Literature DB >> 21962726

African American patients seeking treatment in the public sector: characteristics of buprenorphine vs. methadone patients.

Shannon Gwin Mitchell1, Sharon M Kelly, Jan Gryczynski, C Patrick Myers, Jerome H Jaffe, Kevin E O'Grady, Yngvild K Olsen, Robert P Schwartz.   

Abstract

BACKGROUND: To expand its public-sector treatment capacity, Baltimore City made buprenorphine treatment accessible to low-income, largely African American residents. This study compares the characteristics of patients entering methadone treatment vs. buprenorphine treatment to determine whether BT was attracting different types of patients.
METHODS: Participants consisted of two samples of adult heroin-dependent African Americans. The first sample was newly admitted to a health center or a mental health center providing buprenorphine (N=200), and the second sample was newly admitted to one of two hospital-based methadone programs (N=178). The Addiction Severity Index (ASI) and the Friends Supplemental Questionnaire were administered at treatment entry and data were analyzed with logistic regression.
RESULTS: BT participants were more likely to be female (p=.017) and less likely to inject (p=.001). Participants with only prior buprenorphine treatment experience were nearly five time more likely to enter buprenorphine than methadone treatment (p<.001). Those with experience with both treatments were more than twice as likely to enter BT (OR=2.7, 95% CI=1.11-6.62; p=.028). In the 30 days prior to treatment entry, BT participants reported more days of medical problems (p=.002) and depression (p=.044), and were more likely to endorse a lifetime history of depression (p<.001).
CONCLUSION: Methadone and buprenorphine treatment provided in the public sector may attract different patient subpopulations. Providing buprenorphine treatment through drug treatment programs co-located with a health and mental health center may have accounted for their higher rates of medical and psychiatric problems and appears to be useful in attracting a diverse group of patients into public-sector funded treatment.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21962726      PMCID: PMC3251709          DOI: 10.1016/j.drugalcdep.2011.09.009

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  14 in total

1.  Beliefs about methadone in an inner-city methadone clinic.

Authors:  Sharon Stancliff; Julie Elana Myers; Stuart Steiner; Ernest Drucker
Journal:  J Urban Health       Date:  2002-12       Impact factor: 3.671

2.  Ambivalence toward methadone treatment among intravenous drug users.

Authors:  A Rosenblum; S Magura; H Joseph
Journal:  J Psychoactive Drugs       Date:  1991 Jan-Mar

Review 3.  Misunderstandings about methadone.

Authors:  J E Zweben; J L Sorensen
Journal:  J Psychoactive Drugs       Date:  1988 Jul-Sep

4.  New data from the Addiction Severity Index. Reliability and validity in three centers.

Authors:  A T McLellan; L Luborsky; J Cacciola; J Griffith; F Evans; H L Barr; C P O'Brien
Journal:  J Nerv Ment Dis       Date:  1985-07       Impact factor: 2.254

5.  Interim methadone treatment compared to standard methadone treatment: 4-month findings.

Authors:  Robert P Schwartz; Sharon M Kelly; Kevin E O'Grady; Devang Gandhi; Jerome H Jaffe
Journal:  J Subst Abuse Treat       Date:  2011-02-24

6.  A randomized controlled trial of interim methadone maintenance.

Authors:  Robert P Schwartz; David A Highfield; Jerome H Jaffe; Joseph V Brady; Carol B Butler; Charles O Rouse; Jason M Callaman; Kevin E O'Grady; Robert J Battjes
Journal:  Arch Gen Psychiatry       Date:  2006-01

Review 7.  From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States.

Authors:  Jerome H Jaffe; Charles O'Keeffe
Journal:  Drug Alcohol Depend       Date:  2003-05-21       Impact factor: 4.492

8.  French field experience with buprenorphine.

Authors:  Marc Auriacombe; Mélina Fatséas; Jacques Dubernet; Jean-Pierre Daulouède; Jean Tignol
Journal:  Am J Addict       Date:  2004

Review 9.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Authors:  R P Mattick; J Kimber; C Breen; M Davoli
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

Review 10.  Sustained-release naltrexone: novel treatment for opioid dependence.

Authors:  Sandra D Comer; Maria A Sullivan; Gary K Hulse
Journal:  Expert Opin Investig Drugs       Date:  2007-08       Impact factor: 6.206

View more
  8 in total

1.  Heroin Use, HIV-Risk, and Criminal Behavior in Baltimore: Findings from Clinical Research.

Authors:  Robert P Schwartz; Sharon M Kelly; Jan Gryczynski; Shannon Gwin Mitchell; Kevin E O'Grady; Jerome H Jaffe
Journal:  J Addict Dis       Date:  2015

2.  Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City.

Authors:  Helena Hansen; Carole Siegel; Joseph Wanderling; Danae DiRocco
Journal:  Drug Alcohol Depend       Date:  2016-05-04       Impact factor: 4.492

Review 3.  Methadone at tapered doses for the management of opioid withdrawal.

Authors:  Laura Amato; Marina Davoli; Silvia Minozzi; Eliana Ferroni; Robert Ali; Marica Ferri
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

4.  Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system.

Authors:  Jan Gryczynski; Jerome H Jaffe; Robert P Schwartz; Kristi A Dušek; Nishan Gugsa; Cristin L Monroe; Kevin E O'Grady; Yngvild K Olsen; Shannon Gwin Mitchell
Journal:  Am J Addict       Date:  2013 May-Jun

5.  A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry.

Authors:  Michael S Gordon; Timothy W Kinlock; Robert P Schwartz; Terrence T Fitzgerald; Kevin E O'Grady; Frank J Vocci
Journal:  Drug Alcohol Depend       Date:  2014-06-02       Impact factor: 4.492

6.  Retention in methadone and buprenorphine treatment among African Americans.

Authors:  Jan Gryczynski; Shannon Gwin Mitchell; Jerome H Jaffe; Sharon M Kelly; C Patrick Myers; Kevin E O'Grady; Yngvild K Olsen; Robert P Schwartz
Journal:  J Subst Abuse Treat       Date:  2013-04-05

7.  Prescription medication exchange patterns among methadone maintenance patients.

Authors:  Celeste M Caviness; Bradley J Anderson; Marcel A de Dios; Megan Kurth; Michael Stein
Journal:  Drug Alcohol Depend       Date:  2012-07-31       Impact factor: 4.492

8.  Buprenorphine Maintenance for Opioid Dependence in Public Sector Healthcare: Benefits and Barriers.

Authors:  Laura G Duncan; Sonia Mendoza; Helena Hansen
Journal:  J Addict Med Ther Sci       Date:  2015-08-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.